On Tuesday, LENZ Therapeutics Inc (NASDAQ: LENZ) opened higher 6.62% from the last session, before settling in for the closing price of $15.57. Price fluctuations for LENZ have ranged from $14.43 to $50.40 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -181.63% annually for the last half of the decade. Company’s average yearly earnings per share was noted -10.92% at the time writing. With a float of $28.17 million, this company’s outstanding shares have now reached $28.59 million.
LENZ Therapeutics Inc (LENZ) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of LENZ Therapeutics Inc is 9.98%, while institutional ownership is 91.31%. The most recent insider transaction that took place on Nov 17 ’25, was worth 261,022. In this transaction Chief Commercial Officer of this company sold 10,000 shares at a rate of $26.10, taking the stock ownership to the 4,733 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 40,000 for $25.60, making the entire transaction worth $1,024,000.
LENZ Therapeutics Inc (LENZ) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.46 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.4) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.71% during the next five years compared to -181.63% drop over the previous five years of trading.
LENZ Therapeutics Inc (NASDAQ: LENZ) Trading Performance Indicators
Check out the current performance indicators for LENZ Therapeutics Inc (LENZ). In the past quarter, the stock posted a quick ratio of 12.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -2.83 in one year’s time.
